Cardiometabolic Disease / MASH / NASH
Indication
MASH / NASH
Assets addressing this indication.
Total attributable cost
$303.2B
$20,346/patient
Drug spend
$1.0B
$64/patient
0% of total cost is drugs
All diagnosed and undiagnosed adult MASH/NASH severity strata (US estimate; upper-bound prevalence context) · US